SIGA is monitoring the growing monkeypox outbreak and supports the response
TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox
Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus
Named 27th on the Forbes List of Best Small Cap Companies
Health Security
We are a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security.
Click here to learn more about how SIGA is monitoring the monkeypox outbreak.
U.S. providers seeking guidance on obtaining TPOXX please visit CDC.gov
For foreign governments or other inquiries about TPOXX (Tecovirimat-SIGA), please contact us at monkeypox@siga.com
(Note: TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox; Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus)
Our Pipeline
Attractive product and market expansion opportunities
Our Team
Experienced team of scientists and business leaders
Our Partners
Rich history of successful partnerships to support our vision
SIGA Technologies Receives Approval from UK for Tecovirimat
Learn More
cURL error 28: Operation timed out after 5000 milliseconds with 0 bytes received